Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes

TY - JOUR

T1 - Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes

AU - Széplaki, Gábor

AU - Szegedi, Róbert

AU - Hirschberg, Kristóf

AU - Gombos, Tímea

AU - Varga, Lilian

AU - Karádi, István

AU - Entz, László

AU - Széplaki, Zoltán

AU - Garred, Peter

AU - Prohászka, Zoltán

AU - Füst, George

N1 - Keywords: Aged; Aged, 80 and over; Biological Markers; Brain Ischemia; C-Reactive Protein; Case-Control Studies; Cerebral Infarction; Complement Activation; Complement C1 Inactivator Proteins; Complement C1r; Complement C3a; Complement C4b; Complement C5a; Complement Membrane Attack Complex; Disability Evaluation; Female; Humans; Male; Mannose-Binding Lectin; Middle Aged; Peptide Fragments; Prognosis; Severity of Illness Index; Stroke; Time Factors

PY - 2009

Y1 - 2009

N2 - OBJECTIVE: According to data from animal models, complement activation plays a major role in the brain injury after acute ischemic stroke. Scarce findings are, however, available on the detection of complement activation products in stroke patients. METHODS: We have measured plasma levels of the five complement activation products (C1rC1sC1inh, C4d, C3a, C5a and SC5b-9) in samples of 26 patients with ischemic stroke upon admission. Twenty-six patients with severe carotid atherosclerosis served as patient controls. RESULTS: Levels of two activation products (SC5b-9 and C4d)) were significantly elevated in the plasma of stroke patients, SC5b-9 levels, exhibited significant positive correlation with the clinical severity of stroke, the severity of neurological deficit, as well as with the level of functional disability. CONCLUSION: These findings suggest that complement activation plays an active role in the development of brain infarct. The measurement of complement activation products might help to determine the clinical prognosis after acute ischemic stroke. Furthermore, there is potential usefulness of complement modulating therapy in ischemic stroke.

AB - OBJECTIVE: According to data from animal models, complement activation plays a major role in the brain injury after acute ischemic stroke. Scarce findings are, however, available on the detection of complement activation products in stroke patients. METHODS: We have measured plasma levels of the five complement activation products (C1rC1sC1inh, C4d, C3a, C5a and SC5b-9) in samples of 26 patients with ischemic stroke upon admission. Twenty-six patients with severe carotid atherosclerosis served as patient controls. RESULTS: Levels of two activation products (SC5b-9 and C4d)) were significantly elevated in the plasma of stroke patients, SC5b-9 levels, exhibited significant positive correlation with the clinical severity of stroke, the severity of neurological deficit, as well as with the level of functional disability. CONCLUSION: These findings suggest that complement activation plays an active role in the development of brain infarct. The measurement of complement activation products might help to determine the clinical prognosis after acute ischemic stroke. Furthermore, there is potential usefulness of complement modulating therapy in ischemic stroke.

U2 - 10.1016/j.atherosclerosis.2008.07.044

DO - 10.1016/j.atherosclerosis.2008.07.044

M3 - Journal article

C2 - 18804761

SN - 0021-9150

VL - 204

SP - 315

EP - 320

JO - Atherosclerosis

JF - Atherosclerosis

IS - 1

ER -